These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 32643971)

  • 1. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
    Tian C; Chen Z; Li Y
    J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
    Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
    Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS
    Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
    Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
    Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
    Suzuki T; Maruyama D; Miyagi-Maeshima A; Nomoto J; Tajima K; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Taniguchi H; Izutsu K; Kobayashi Y; Tobinai K
    Cancer Med; 2021 Aug; 10(15):5101-5109. PubMed ID: 34105893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.
    Davies A; Barrans S; Burton C; Mercer K; Caddy J; Chinnery F; Day L; Fernando D; Ardeshna K; Collins G; Radford J; Rule S; McMillan A; Johnson P; Griffiths G
    F1000Res; 2020; 9():941. PubMed ID: 33093947
    [No Abstract]   [Full Text] [Related]  

  • 10. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
    Major A; Smith SM
    Clin Adv Hematol Oncol; 2021 Nov; 19(11):698-709. PubMed ID: 34807015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution.
    Liang Y; Liu X; Yang J; Wang H; Piao Y; Wei L; Wang L
    Chin Med J (Engl); 2023 Jan; 136(2):167-175. PubMed ID: 36780421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Center Analysis of Characteristics and Outcomes of De Novo, Concurrent, and Transformed Diffuse Large B-Cell Lymphoma.
    Desai S; Chaturvedi M; Hameed R; Baez-Sosa V; Shenoy AG
    Oncologist; 2021 Sep; 26(9):e1660-e1663. PubMed ID: 34097758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
    Zhang MC; Fang Y; Wang L; Cheng S; Fu D; He Y; Zhao Y; Wang CF; Jiang XF; Song Q; Xu PP; Zhao WL
    Clin Epigenetics; 2020 Oct; 12(1):160. PubMed ID: 33097085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of bone marrow retention index and bone marrow-to-liver ratio of baseline 18F-FDG PET/CT in diffuse large B-cell lymphoma.
    El-Azony A; Basha MAA; Almalki YE; Abdelmaksoud B; Hefzi N; Alnagar AA; Mahdey S; Ali IM; Nasr I; Abdalla AAEM; Yousef HY; Zaitoun MMA; Elsayed SB; Nada MG; Amin MI; Hassan RM; Ali SA; Dawoud TM; Aly SA; Algazzar YH; Abdelhamed H
    Eur Radiol; 2024 Apr; 34(4):2500-2511. PubMed ID: 37812294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rituximab plus Autologous Hemotopoietic Stem Cell Transplantation for The Treatment of CD5 Positive Diffuse Large B Cell Lymphoma with Autoimmune Hemolytic Anemia].
    Huang YQ; Zheng RJ; Wu RJ; Ma XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):722-6. PubMed ID: 27342498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
    Morgenstern Y; Aumann S; Goldschmidt N; Gatt ME; Nachmias B; Horowitz NA
    Cancer Med; 2021 Dec; 10(24):8866-8875. PubMed ID: 34816617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China.
    Sun JJ; Liu L; Wang JR; Shen YZ; Qi TK; Wang ZY; Tang Y; Song W; Chen J; Zhang RF
    Chin Med J (Engl); 2020 Dec; 133(23):2796-2802. PubMed ID: 33273327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.